/ /

  • linkedin
  • Increase Font
  • Sharebar

    Treating UTIs in the age of antibiotic resistance: Strategies for the practicing OB/GYN



    It is likely that ob/gyns will encounter MDR pathogens previously seen only in the critical care areas that will now occur in both the inpatient and outpatient obstetrical settings. Previous exposure to antibiotics, hospitalization, and the presence of an indwelling catheter increase the risk of resistant organisms. As antibiotic resistance is becoming more widespread, awareness of antibiotic sensitivities and consultation with infectious disease specialists in cases of MDR infections will help practitioners to provide optimum care in these difficult cases. In cases of ESBL-associated UTIs, it is important to obtain a test of cure 10 to 14 days after treatment to confirm eradication of the infection. Carbapenems, fosfomycin, and newer cephalosporin/beta-lactamase inhibitors appear safe for use in pregnancy and provide activity against ESBL-producing Enterobacteriaceae that are resistant to our previously used therapies. Strategies such as good handwashing, contact precautions when dealing with patients with resistant organisms, and appropriate antibiotic stewardship (limiting the use of unnecessary antibiotics, limiting broad-spectrum antibiotics when a narrow agent is available, institutional antibiotic cycling) will help us to better deal with these infections in the future.

    Take-home points

    MDRO urinary tract infections are now being seen in the community at higher frequencies with ESBL-producing E coli increasing from 7.8% to 18.9% in the US from 2010 to 2014.

    Consider antibiotic resistance for infections that do not respond to conventional therapy.

    Be knowledgeable of  local antibiograms when treating UTIs empirically. Obtain culture and sensitivities studies on all patients at higher risk for antibiotic resistance.



    1. Glaser A, Schaeffer A. Urinary Tract Infection and Bacteriuria in Pregnancy Urol Clin N Am 2015;42:547-60

    2. Wing D, Fassett M, Getahun D. Acute Pyelonephritis in Pregnancy; an 18-year retrospective analysis. Am J Obstet Gynecol 2014:210:219e1-6.

    3. Adler A, Katz D, Marchaim D. The Continuing Plague of Extended-spectrum b-lactamase–producing Enterobacteriaceae Infections. Infect Dis Clin N Am 2016;30: 347–375

    4.  Doi Y, Park Y, Rivera J, Adams-Haduch J, Hingwe A, Sordillo E, Lewis J, Howard W, Johnson L, Polsky B, Jorgensen J, Richte S, Shutt K, Paterson D. Community-Associated Extended-Spectrum β-Lactamase–Producing Escherichia coli Infection in the United States. Clin Infect Dis 2013;56:641–8.

    5. Pelig A, Hooper D. Hospital-Acquired Infections due to Gram-Negative Bacteria. NEJM 2010;362:1804-13

    6. Lob S, Nicolle L, Hoban D, Kazmierczak K, Badal R, Sahm D. Susceptibility patterns and ESBL rates of Escherichia from urinary tract infections in Canada and the United States, SMART 2010-2014. Diagn Microbiol Infect Dis 2016; 85: 459-65

    7. Eppes C, Clark S. Extended-spectrum b-lactamase infections during pregnancy: a growing threat. Am J Obstet Gynecol 2015;213:650-652.

    8.  The Center for Disease Control. Antimicrobial/Antibiotic Resistance: Biggest Threats. http://www.cdc.gov/drugresistance/biggest_threats.html. Accessed July 19, 2016

    9. Vazquez J, Abalos E. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database of Systematic Reviews. 2011, Issue 1. Art. No.: CD002256.

    10.  Michalopoulos A, Livaditis I, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011;15: e732–e739.

    11. Estebanez A, Pascual R, Gil V, Ortiz F, Santibáñez M, Pérez Barba C. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis 2009;28:1457-1464.

    12. Khawaja A, Khan F, Dar T, Bhat A, Wani M, Wazir B. Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study. Cent European J Urol. 2015;68:371-375.

    13.  Falagas M, Kastoris A, Kapaskelis A, Karageorgopoulos D. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing Enterobacteriaceae infections: a systemic review. Lancet Infect Dis 2010;10:43-50.

    14. Vardakas K, Legakis N, Triarides N, Falgas M. Susceptibility of contemporary isolates to fosfomycin; a systemic review of the literature. Int J Antimicrob Agents 2016; 47:269-285.

    15.  Papp-Wallace K, Endimiani A, Taracilia M, Bonomo R. Carbapenems: Past, Present, and Future Antimicrob Agents Chemother 2011;55:4943-4960.

    16. Zhanel G, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban D, Noreddin A, Karlowsky J. Comparative review of the carbapenems. Drugs. 2007;67:1027-1052.

    17. Veve M, Wagner J, Kenney R, Grunwald J, Davis S. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Internat J Antimicrob Agents 2016; 48: 56–60.

    18. Doi Y, Paterson D. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med. 2015;36:74-84.

    19. Khatri A, Murphy N, Wiest P, Osborn M, Garber K, Hecker M, Hurless K, Rudin S, Jacobs M, Kalayjian R, Salata R, Duin D, Perez F, Bonomo R. Community –Acquired Pyelonephritis in Pregnancy Caused by KPC Producing Klebsiella Pneumoniae. Antimicrob Agents Chemother 2015; 59:4375-4378.

    20. Mawal Y, Critchley I, Riccobene T, Talley A. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Expert Rev Clin Pharmacol 2015:8:691-707.

    21. Sharma R, Park T, Moy S. Caftazadime-Avibactam: A novel cephalosporin/beta-lactamase Inhibitor combination for the treatment of resistant gram negative organisms. Clin Therap 2016;38:431-444.

    22. Giamarellou H, Poulakou G. Multidrug-Resistant Gram-Negative Infections. What are the Treatment Options? Drugs 2009; 69 (14): 1879-1901

    Christopher Hicks, MD
    Dr Hicks is Resident in the Department of Obstetrics and Gynecology, Bridgeport Hospital, Bridgeport, Connecticut.
    Zane Saul, MD
    Dr Saul is Chief, Section of Infectious Disease, Department of Internal Medicine, Bridgeport Hospital, Bridgeport, Connecticut, and ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    Latest Tweets Follow